New response evaluation criteria in solid tumours - Revised RECIST Guideline (version 1.1)

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 13, 2009, Pages 2495-2501

  Watanabe, Hirokazu ^a   Okada, Morihito ^b   Kaji, Yasushi ^c   Satouchi, Miyako ^d   Sato, Yozo ^e   Yamabe, Yuichiro ^f   Onaya, Hiroaki ^g   Endo, Masahiro ^h   Sone, Miyuki ⁱ   Arai, Yasuaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d HYOGO CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f TOCHIGI CANCER CENTER   (Japan)

^g NATIONAL CANCER CENTER   (Japan)

^h SHIZUOKA CANCER CENTER   (Japan)

ⁱ IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Clinical trial; RECIST

Indexed keywords

PRACTICE GUIDELINE; REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

EID: 79959778715     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
2. Watanabe H, Yamamoto S, Kunitoh H, et al: Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci 94: 1015-1020, 2003. (Pubitemid 37508986)
3. Eisenhauer EA, P. Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
4. WHO Handbook for Reporting Results of Cancer Treatment, Offset Publication, No. 48, World Health Organization, Geneva (Switzerland), 1979.
5. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990. (Pubitemid 20195640)
6. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586, 2007. (Pubitemid 350002966)
7. Watanabe H, Kunitoh H, Yamamoto S, et al: Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. Cancer Sci 97: 214-218, 2006.
8. Schwartz LH, Bogaerts J, Ford R, et al: Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 45: 261-267, 2009.
9. Ford R, Schwartz L, Dancey J, et al: Lessons learned from independent central review. Eur J Cancer 45: 268-274, 2009.
10. Bogaerts J, Ford R, Sargent D, et al: Individual patient data analysis to assess modifications to the RECIST criteria Eurf Cancer 45: 248-260, 2009.
11. Dancey JE, Dodd LE, Ford R, et al: Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 45: 281-289, 2009.
12. Sargent D, Rubinstein L, Schwartz L, et al: Validation of novel imaging methodologies for use as cancer clinical trials end-points. Eur J Cancer 45: 290-299, 2009.
13. Moskowitz CS, Jia X, Schwartz LH, et al: A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 45: 300-310, 2009.
14. JCOG Excerpta Medica, Japan/Elsevier Science, 2002.
15. RECIST guidelines 2003, pp157-166.